Collegium Pharmaceutical Inc (COLL) 2023年年度报告「NASDAQ」.pdf

1、04UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM 10-KANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the year ended December 31,2023ORTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the transit

2、ion period from to Commission File Number 001-37372Collegium Pharmaceutical,Inc.(Exact name of registrant as specified in its charter)Virginia(State or other jurisdiction of incorporation or organization)03-0416362(I.R.S.Employer Identification Number)100 Technology Center DriveStoughton,MA(Address

3、of principal executive offices)02072(Zip Code)(781)713-3699(Registrants telephone number,including area code)Securities registered pursuant to Section 12(b)of the Act:Title of each classTrading Symbol(s)Name of exchange on which registered:Common stock,par value$0.001 per shareCOLLThe NASDAQ Global

4、Select MarketSecurities registered pursuant to Section 12(g)of the Act:NoneIndicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or S

5、ection 15(d)of the Act.Yes No Indicate by check mark whether the registrant:(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 during the preceding 12 months(or for such shorter period that theregistrant was required to file such reports),and(2

6、)has been subject to such filing requirements for the past 90 days.Yes No Indicate by check mark whether the registrant has submitted electronically,every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T(232.405 of this chapter)during the preceding 12 months(or f